Sanofi’s Altuviiio Set To Reenergize Factor VIII Space
The once-weekly Factor VIII replacement therapy for hemophilia A, newly approved by the US FDA, appears well positioned to compete with Roche’s blockbuster Hemlibra.
You may also be interested in...
Altuviiio May See Rapid Uptake Upon European Approval In Hemophilia A
Sanofi announced results from its XTEND-Kids trial, clearing the last requirement before an anticipated second half filing for Altuviiio’s approval with the EMA.
BioMarin Hopes A Single Warranty Will Make Gene Therapy Reimbursement Simpler
The management team talked to Scrip at J.P. Morgan about plans for launching the first gene therapy for hemophilia A in Europe and the US, and its unique approach to reimbursement.
Sanofi Looks To Dominate $5bn Hemophilia A Factor Market After Trial Success
Phase III success for efanesoctocog alfa sets up a filing in the near future, and a chance to seize market share from existing Factor VIII products, as well as Roche’s Hemlibra.